CAMBRIDGE, Mass. , May 27, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics , Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced

Veteran life sciences financial executive brings over 25 years finance and capital markets expertise CAMBRIDGE, Mass., Feb. 8, 2021 /PRNewswire/ -- Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to

Financing accelerates Werewolf's pipeline of systemically delivered, conditionally activated INDUKINE™ molecules into clinical stage development and supports efforts to build a leading immuno-oncology drug discovery and development team CAMBRIDGE, Mass., Jan.

Expansion of leadership team with deep translational oncology drug development expertise as Company prepares for clinical development of lead programs CAMBRIDGE, Mass., Nov. 9, 2020 /PRNewswire/ -- Werewolf Therapeutics, Inc., an oncology biotherapeutics company developing next-generation,

CAMBRIDGE, Mass., Aug. 10, 2020 /PRNewswire/ -- Werewolf Therapeutics, Inc., an oncology biotherapeutics company developing next-generation, transformative cancer therapeutics, today announced the appointment of Ellen Lubman to the company's newly created position of Chief Business Officer.

Designing conditionally activated therapeutics that unleash a powerful attack on cancer cells Company led by experienced team with proven track record of developing novel medicines for the treatment of cancer CAMBRIDGE, Mass., Nov. 20, 2019 /PRNewswire/ -- Werewolf Therapeutics, an oncology